Five-year outcomes of the S1106 study of R-hyper-CVAD vs R-bendamustine in transplant-eligible patients with mantle cell lymphoma

Long term results of a study comparing two different regimens of rituximab based therapy for first line treatment of mantle cell lymphoma.